Q4 2025 Bactiguard Holding AB Earnings Call Transcript
Key Points
- Bactiguard Holding AB (FRA:5JE) reported a strong Q4 with an EBITDA of SEK25 million, driven by an updated agreement with Zimmer Biomet.
- The company achieved a 10% increase in net sales for Q4, excluding currency effects.
- Bactiguard Holding AB (FRA:5JE) has strengthened partnerships with BD and Zimmer Biomet, reflecting solid collaboration and future growth potential.
- The Wound Management portfolio, particularly Hydrocyn, showed double-digit growth across product lines.
- The company is on track towards its 2030 targets, focusing on licensed partnerships and profitable growth in the Wound Management portfolio.
- Total revenue decreased in 2025, primarily due to negative currency effects and discontinued business.
- The sutures segment within the Wound Management portfolio experienced a larger than expected decline in revenues.
- The Zimmer Biomet agreement was updated to reflect a non-exclusive arrangement, potentially limiting immediate revenue growth.
- The transition to MDR regulatory compliance is ongoing, which may pose challenges and require further investment.
- Despite positive EBITDA, the full-year net result was a negative SEK8 million, indicating ongoing financial challenges.
Welcome to the Bactiguard Q4 2025 report presentation. (Operator Instructions)
Now I will hand the conference over to the speakers, CEO, Christine Lind and CFO, Patrick Bach. Please go ahead.
Thank you, Operator, and welcome to the presentation of Bactiguard's fourth quarter as well as the full year 2025. Our CFO, Patrick Bach and I will go through the presentation together and at the end, there will be time for your questions.
Let's start with some high-level comments on the quarter and summarize 2025. Patrick will go into more details on the financials later in the presentation.
We close the year with a great Q4. Total revenues increased by more than 4% when excluding the negative effect of currency. Given our substantial US dollar exposure within the licensed business, the weaker dollar does continue to impact our revenues negatively.
The main driver for both the fourth quarter and full year on revenues and EBITDA was the updated agreement with Zimmer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
